Elucidation of molecular mechanism of cervical cancer and its clinical application

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462540
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Fujita Health University
• Principal Investigator: Fujii Takuma 藤田保健衛生大学, 医学部, 教授 (10218969)
• Co-Investigator(Renkei-kenkyūsha): Takayanagi Atsushi 慶應義塾大学, 医学部, 講師 (80245464)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: human papillomavirus / vaccine / cervical cancer

Outline of Final Research Achievements

Monitoring the attribution of human papillomavirus (HPV) genotypes to cervical precancerous lesions is essential for evaluating the potential efficacy of HPV vaccines. Three procedures, Clinichip HPV test (Chip) and modified GP5+/6+ PCR coupled to fluorescent bead sorter detection (MGP) in exfoliated cervical cells (C-Chip and C-MGP, respectively) or formalin-fixed paraffin-embedded tissues (F-MGP), were compared to determine the appropriate genotyping procedures. In CIN 2/3 specimens, HPV16/18/31/33/45/52/58 hierarchical attribution was 88.4% (76/86) with C-Chip, 86.0% (74/86) with C-MGP, and 83.7% (72/86) with F-MGP (p = 0.49). Although F-MGP is theoretically a reliable method for determining HPV genotype attribution, it is acceptable to use C-Chip or C-MGP, coupled to the hierarchical attribution formula to correct the bias of multiple infections. These approaches using exfoliated cervical cells are practical for monitoring the efficacy of HPV vaccines.

Free Research Field

gynecology